Richter Transformation clinical trials at UCSF
1 research study open to eligible people
Richter transformation occurs when chronic lymphocytic leukemia turns into a more aggressive cancer. UCSF is conducting studies with a drug called NX-1607 to assess its safety in patients. The trials also measure how this medication affects the cancer's growth.
Showing trials for
NX-1607 in Adults With Advanced Malignancies
open to eligible people ages 18 years and up
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
San Francisco, California and other locations
Our lead scientists for Richter Transformation research studies include Pamela Munster.
Last updated: